Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Non-Current Debt (2017 - 2021)

Historic Non-Current Debt for Sunshine Biopharma (SBFM) over the last 5 years, with Q4 2021 value amounting to $1.9 million.

  • Sunshine Biopharma's Non-Current Debt rose 10020.95% to $1.9 million in Q4 2021 from the same period last year, while for Dec 2021 it was $1.9 million, marking a year-over-year increase of 10020.95%. This contributed to the annual value of $1.9 million for FY2021, which is 10020.95% up from last year.
  • Per Sunshine Biopharma's latest filing, its Non-Current Debt stood at $1.9 million for Q4 2021, which was up 10020.95% from $3.2 million recorded in Q3 2021.
  • Sunshine Biopharma's 5-year Non-Current Debt high stood at $3.2 million for Q3 2021, and its period low was $63234.0 during Q2 2020.
  • For the 5-year period, Sunshine Biopharma's Non-Current Debt averaged around $1.0 million, with its median value being $312566.0 (2018).
  • Examining YoY changes over the last 5 years, Sunshine Biopharma's Non-Current Debt showed a top increase of 314859.25% in 2021 and a maximum decrease of 10020.95% in 2021.
  • Over the past 5 years, Sunshine Biopharma's Non-Current Debt (Quarter) stood at $79710.0 in 2017, then skyrocketed by 263.63% to $289847.0 in 2018, then dropped by 0.01% to $289825.0 in 2019, then skyrocketed by 227.44% to $949006.0 in 2020, then soared by 100.21% to $1.9 million in 2021.
  • Its last three reported values are $1.9 million in Q4 2021, $3.2 million for Q3 2021, and $2.1 million during Q2 2021.